SMC - June 2024 decisions

10 June 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - May 2024 decisions

13 May 2024 - The SMC has today published advice on two medicines. ...

Read more →

SMC - March 2024 decisions

11 March 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - February 2024 decisions

12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - January 2024 decisions

15 January 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - December 2023 decisions

11 December 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - November 2023 decisions

13 November 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Lynparza (olaparib) accepted for use in Scotland as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer

9 October 2023 - First and only approved medicine in Scotland which targets germline (hereditary) BRCA mutations in early breast cancer ...

Read more →

AbbVie’s Aquipta (atogepant) is now available in Scotland for the prevention of migraines in adults

9 October 2023 - The SMC has accepted Aquipta (atogepant), the oral, once daily calcitonin gene-related peptide receptor antagonist for restricted ...

Read more →

SMC - October 2023 decisions

9 October 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC - September 2023 decisions

11 September 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

Scottish Medicines Consortium accepts Vazkepa (icosapent ethyl) to help reduce cardiovascular risk for patients in Scotland

7 August 2023 - Vazkepa already commercially available in England, Wales, and Northern Ireland where NICE recommended its reimbursement and use ...

Read more →

SMC - August 2023 decisions

7 August 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

SMC - July 2023 decisions

10 July 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC accepts Rinvoq (upadacitinib) as a treatment option for adults with moderately to severely active Crohn’s disease in Scotland

12 June 2023 - The SMC decision is supported by data from three Phase 3 clinical trials demonstrating upadacitinib achieved ...

Read more →